Results 141 to 150 of about 396,954 (353)
The cytokine IL-12p70 is crucial for T helper 1 (Th1) polarization and the generation of type 1 immunity required to fight cancer and pathogens. Therefore, strategies to optimize the production of IL-12p70 by human dendritic cells (DCs) may significantly
Brian C. Gilmour+2 more
doaj +1 more source
Corrigendum: Lipid metabolism in tumor immunology and immunotherapy. [PDF]
Duong LK+8 more
europepmc +1 more source
Tumor Immunology, Immunotherapy and Cancer Vaccines [PDF]
Jonathan A. Ledermann
openalex +1 more source
Objective Metabolic syndrome (MetS) is a known comorbidity of psoriatic arthritis (PsA) and is associated with PsA disease activity. We aimed to explore the association between MetS and radiographic features (peripheral and axial) in PsA. Methods We included patients with PsA followed at our prospective observational cohort for the period between 1978 ...
Fadi Kharouf+6 more
wiley +1 more source
The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response
IL-37 is a member of the IL-1 superfamily exerting anti-inflammatory functions in a number of diseases. Extracellular IL-37 triggers the inhibitory receptor IL-1R8 that is known to regulate different NK cell pathways and functional activities including ...
Nadine Landolina+8 more
doaj +1 more source
Lipid metabolism in tumor immunology and immunotherapy. [PDF]
Duong LK+8 more
europepmc +1 more source
TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer. [PDF]
Tumor antigen-driven selection may expand T cells having T cell receptors (TCRs) of shared antigen specificity but different amino acid or nucleotide sequence in a process known as TCR convergence. Substitution sequencing errors introduced by TCRβ (TCRB)
Conroy, Jeffrey+7 more
core
Diverse Treatment Goals in Psoriatic Arthritis: Insights from participants in the PARC cohort
Objective The aim was to examine patient‐reported treatment goals among individuals with psoriatic arthritis (PsA). Methods Participants in the Psoriatic Arthritis Research Consortium (PARC) completed standardized assessments including patient‐reported outcome (PROs) instruments between 2017‐2020.
Astia Allenzara+8 more
wiley +1 more source